HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Pacira BioSciences (NASDAQ:PCRX) and maintained a price target of $57.
July 02, 2024 | 5:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Pacira BioSciences and maintained a price target of $57, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $57 price target by HC Wainwright & Co. suggests strong confidence in Pacira BioSciences' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100